Risk Disclosure In Drug Ads Will Be FDA’s Focus After House Defeats DTC Ban
Executive Summary
The revised language on direct-to-consumer advertising in the FDA safety bills pending in Congress no longer allows the agency to ban ads, but creates a number of new disclosure requirements for the spots
You may also be interested in...
Pressure For More DTC Ad Regulation Begins Again With PDUFA V
Industry should be prepared for the fight over user fees for direct-to-consumer advertising to be revived during the fifth round of reauthorization of the Prescription Drug User Fee Act
Pressure For More DTC Ad Regulation Begins Again With PDUFA V
Industry should be prepared for the fight over user fees for direct-to-consumer advertising to be revived during the fifth round of reauthorization of the Prescription Drug User Fee Act
Pharma Ads Must Get Back To Basics, Key Lobbyist Says
Jim Davidson tells marketers to remember why ads are important as they push back on attempts to curb spending.